NCT lookup

Inclusion Criteria:

* Metaplastic Infiltrating adenocarcinoma of the breast
* HER2 Overexpression by IHC and / or amplification (FISH and or ICHS)
* Positive diagnosis of neoplastic meningitis: positive CSF cytology (obtained within 28 days before inclusion) AND / OR clinical symptoms of neoplastic meningitis and aspect of tumoral meningitis on MRI
* Brain metastases are allowed without prior treatment, if they are asymptomatics and without engagement. In cases of symptomatic brain metastases, subjects could be included only if surgery and / or radiotherapy (stereotactic or in toto) were performed and if the cerebral metastatic localization allow IT or intra-ventricular treatment. The last radiotherapy session or the surgery must have been done 3 weeks before.
* Aged 18 years old or more
* Male and female
* Life expectancy more than 2 months
* Satisfactory Cardiac function: left ventricular ejection fraction (LVEF) determined by ultrasound scan or myocardial scintigraphy
* Adequate Biological functions 14 days before inclusion, according to the criteria below: Neutrophils \> 1.0 x 109/L, Hemoglobin \> 9.0 g/dL (+ transfusion if needed,Platelets \> 50 x 109/L,Bilirubin \< 3 x N, ALT \& AST \< 10 x N, Creatinine \< 2.0 mg/dL, Clearance \> 25 mL/min (Cockcroft and Gault formula), Prothrombin time \> 70 %, Kaolin cephalin coagulation time \< 1.5 x N.
* Women of childbearing potential, must take adequate birth control measure during the study period and must have a negative pregnancy test (BetaHCG serum)
* The subjects must perform all evaluations of pre-inclusion, as provided by the protocol
* Signed written inform consent

Exclusion Criteria:

* CSF circulation disorders suspected on MRI brain (obstructive hydrocephalus) or medullar (obstacle) with, in case of a focal radiotherapy on obstructive lesion, checking the restoration of transit traffic by isotope CSF
* Anti-coagulant effective dose treatment when trastuzumab administration by lumbar puncture
* Patient on Lapatinib (wash out\> 2 weeks from the date of first dose intrathecal trastuzumab)
* Known or suspected trastuzumab allergy
* Contraindications of trastuzumab administration, including cardiac diseases: LVEF \<laboratory lower limit of normal or any other heart condition which would expose the subject to an unreasonable risk if he were to participate in the study
* Severe toxicity unresolved or unstable related to another previous study restricted drug and / or a cancer treatment
* Ventriculoperitoneal or atrial shunting excepted if the valve could be turn off (on-off switch) and the patient can stand it during 6 h after each injection of trastuzumab
* Dementia, altered mental status or psychiatric condition that would prevent the subject to understand or give informed consent
* Pre-existing severe cerebrovascular disease, such as stroke in a major vessel, vasculitis in the central nervous system or malignant hypertension
* Uncontrolled infection
* Participation in a clinical study with an experimental molecule
* No affiliation to a Social insurance (beneficiary or assignee)
* Pregnant women, breastfeeding or of childbearing age not taking contraceptive
* Subject unable to make follow up schedule
* Persons deprived of liberty or under guardianship (including curators)

• Caen, Calvados, France
• Saint-Cloud, Haut de Seine, France
• Lille, Nord, France
• Lyon, Rhone, France
• Bordeaux, France
• Grenoble, France
• Montpellier, France
• Toulouse, France
• Paris, Île-de-France Region, France
• Paris, Île-de-France Region, France